AstraZeneca disclosed that its oral breast cancer agent camizestrant did not succeed in a pivotal trial that tested it as a first-line therapy for advanced tumors. In the study, a regimen containing camizestrant plus another medicine failed to outperform the current standard treatment on a primary measure of how long patients went before their cancer progressed.
The company had recently received accelerated approval in the U.S. for camizestrant in a more limited setting: as a treatment for patients whose tumors develop a specific mutation indicative of emerging drug resistance. According to the source, the new pivotal-trial result means the broader first-line indication that might have substantially increased the drug’s potential patient population will not materialize from this trial.
The STAT coverage linked in the column emphasizes that the failed outcome concerns a comparison on progression timing, and that the trial’s lack of superiority versus standard therapy is the reason the drug will not immediately expand into a larger first-line market on the basis of this study.
Scholar Rock received U.S. FDA approval for Isembyld, described in the source as the first-ever therapy that targets the loss of muscle in spinal muscular atrophy (SMA). The approval covers adults and children aged 2 years and older who are already receiving SMA therapies that act on SMN2, the gene central to neuronal survival in SMA.
The STAT article frames the approval as an important step for patients with this rare, progressive neurological disorder that progressively destroys the nerve cells controlling movement, breathing, and speaking. The piece notes the grave natural history of untreated infants with SMA, stating that babies who go untreated usually die by age 2, which underscores the clinical importance of incremental therapeutic advances in the disease.
The column highlights that a failed pivotal trial in a first-line advanced-breast-cancer setting can limit a drug’s clinical reach. For camizestrant, the source explains that although it had earlier received accelerated approval for a mutation-associated indication, the unsuccessful pivotal trial curtails the likelihood that camizestrant will be adopted more widely as an initial therapy for advanced breast cancer based on this study.
The item in the column connects two related points drawn from the STAT reporting: regulatory status already granted under an accelerated approval pathway for a niche indication, and the pivot back to a smaller patient population following a negative outcome in a larger, confirmatory trial intended to expand use. The column does not provide additional trial design details, numerical endpoints, or subgroup results; those specifics were not reported in the source column and are available in the linked STAT stories.
According to the source, the FDA approved Isembyld for use in adults and children 2 years and older who are currently receiving SMN2-targeting SMA therapies. The column presents Isembyld as the first therapy specifically addressing muscle loss in SMA and positions the approval as a hopeful development for patients who may gain improved function, including movement and independent walking.
The article highlights the progressive and severe nature of SMA and frames the approval as another incremental therapeutic advance for a disease where early and effective interventions are critical. The column does not provide dosing, safety profile, or trial outcome numbers in this brief summary; those clinical details were not reported in the source column and should be sought in the linked STAT reporting or the FDA approval documents.
The Pharmalittle column also notes other items of interest on the STAT site, including coverage about a potential Novo company rebrand or name change. The column points readers to related STAT stories for deeper reporting on those items.
This Pharmalittle piece is published as a STAT+ item and includes links to full STAT coverage. The column is authored by Ed Silverman and dated Sept. 14, 2026. Portions of the reporting are exclusive to STAT+ subscribers; the column indicates that the remainder of the story and additional in-depth analysis require a STAT+ subscription. The source column does not reproduce the full underlying STAT+ articles and does not include extended clinical data beyond the summarized updates.